Desai, K., McManus, J. M. & Sharifi, N. Hormonal therapy for prostate cancer. Endocr. Rev. 42, 354–373 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941).

CAS  Google Scholar 

Stanbrough, M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815–2825 (2006).

Article  PubMed  CAS  Google Scholar 

Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447–4454 (2008).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Holzbeierlein, J. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217–227 (2004).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742–3748 (2009).

Article  PubMed  CAS  Google Scholar 

Potter, G. A., Barrie, S. E., Jarman, M. & Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P45017 α (17 α-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463–2471 (1995).

Article  PubMed  CAS  Google Scholar 

Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

Article  PubMed  CAS  Google Scholar 

de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Ryan, C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16, 152–160 (2015).

Article  PubMed  CAS  Google Scholar 

James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496–1501 (2010).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).

Article  Google Scholar 

Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Geng, C. et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 74, 5631–5643 (2014).

Article  PubMed  PubMed Central  CAS  Google Scholar 

An, J., Wang, C., Deng, Y., Yu, L. & Huang, H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 6, 657–669 (2014).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gan, W. et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59, 917–930 (2015).

Article  PubMed  PubMed Central  CAS  Google Scholar 

An, J. et al. Truncated ERG oncoproteins from TMPRSS2–ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59, 904–916 (2015).

Article  PubMed  CAS  Google Scholar 

Groner, A. C. et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 29, 846–858 (2016).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li, C. et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 30, 4350–4364 (2011).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shi, L. et al. Mutated SPOP E3 ligase promotes 17βHSD4 protein degradation to drive androgenesis and prostate cancer progression. Cancer Res. 81, 3593–3606 (2021).

Article  PubMed  CAS  Google Scholar 

Blattner, M. et al. SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling. Cancer Cell 31, 436–451 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Swami, U. et al. Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer. Eur. Urol. 78, 652–656 (2020).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nakazawa, M. et al. Clinical and genomic features of SPOP-mutant prostate cancer. Prostate 82, 260–268 (2022).

Article  PubMed  CAS  Google Scholar 

Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230–3238 (2020).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Swami, U. et al. SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 28, 4917–4925 (2022).

Article  PubMed  CAS  Google Scholar 

Boysen, G. et al. SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity. Clin. Cancer Res. 24, 5585–5593 (2018).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Stockdale, C., Flaus, A., Ferreira, H. & Owen-Hughes, T. Analysis of nucleosome repositioning by yeast ISWI and CHD1 chromatin remodeling complexes. J. Biol. Chem. 281, 16279–16288 (2006).

Article  PubMed  CAS  Google Scholar 

Lusser, A., Urwin, D. L. & Kadonaga, J. T. Distinct activities of CHD1 and ACF in ATP-dependent chromatin assembly. Nat. Struct. Mol. Biol. 12, 160–166 (2005).

Article  PubMed  CAS